Cytomedix to Host 2011 Financial Results Conference Call on Friday, March 30, 2012

GAITHERSBURG, MD (March 20, 2012) ï Cytomedix, Inc. (OTC/BB: CMXI), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that the Company will release financial results for the three and twelve months ended December 31, 2011, following the close of the market on Thursday, March 29, 2012.

Martin Rosendale, Chief Executive Officer, and Andrew Maslan, Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time on Friday, March 30, 2012, to discuss the fourth quarter and year end 2011 financial results and to answer questions. Shareholders and other interested parties may participate in the call by dialing 888-679-8034 (domestic) or 617-213-4847 (international) and entering passcode 23291244. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com.

A replay of the conference call will be available beginning two hours after its completion through April 6, 2012 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 78509324. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com.

About Cytomedix, Inc.

Cytomedix, Inc. develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGelÊ System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell ("ALDH^{br}") technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit www.cytomedix.com

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedixôactual results may differ materially due to a number of factors, many of which are beyond Cytomedixôability to predict or control, including many among others, risks and uncertainties related to the Companyôs ability to successfully integrate this acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and intergrated business enterprise, viability and effectiveness of the Companyôs sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGelÊ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as ñbelieves", "forecasted,"

"projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2010, filed with the SEC and other subsequent filings. These filings are available at http://www.sec.gov.

Contacts:

Cytomedix, Inc.
Martin Rosendale, Chief Executive Officer
Andrew Maslan, Chief Financial Officer
David Jorden, Executive Chairman
(240) 499-2680

Investor Inquiries
Anne Marie Fields
LHA
(afields@lhai.com
(212) 838-3777

Bruce Voss
LHA
(bvoss@lhai.com)
(310) 691-7100
@LHA_IR_PR

Media Inquiries
Michelle Linn
Linnden Communications
(linnmich@comcast.net)
(508) 362-3087

# # #